Glucagon-Like Peptide-1 Receptor Agonists in Asthma and Obesity-Associated Asthma: A Systematic Review of Clinical Outcomes and Translational Mechanisms.
Saeed Saadat, Timothy G Chow, Yixin Tang et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the effects of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on asthma outcomes, particularly in individuals with obesity and type 2 diabetes. The review found that GLP-1RA use was associated with reduced asthma exacerbations and healthcare utilization. However, the evidence is limited by confounding factors and the need for further randomized controlled trials to establish causality.
Key findings
- GLP-1RA use was associated with reduced asthma exacerbations and healthcare utilization in populations with obesity and/or type 2 diabetes.
- Associations persisted after adjusting for body mass index or glycemic markers.
- Preclinical models showed reductions in airway inflammation and hyper-responsiveness, but with substantial risk of bias.
Why it matters
Understanding the potential benefits of GLP-1RAs in asthma management could inform treatment strategies, especially for patients with obesity or metabolic dysfunction. This may lead to improved clinical outcomes in a population that often faces challenges in asthma control.